A Phase 1b/2, Open Label, Randomized, Repeat Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Biological Activity, and Pharmacokinetics of ND-L02-s0201 Injection, A Vitamin A-coupled Lipid Nanoparticle Containing siRNA Against HSP47, in Subjects With Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4).
Phase of Trial: Phase I/II
Latest Information Update: 17 May 2017
At a glance
- Drugs ND L02 s0201 (Primary)
- Indications Fibrosis
- Focus Adverse reactions
- Acronyms METAVIR F3-4
- Sponsors Nitto Denko
- 08 Jun 2016 Status changed from active, no longer recruiting to completed.
- 10 Dec 2015 Planned primary completion date changed from 1 Apr 2016 to 1 May 2016 as per ClinicalTrials.gov.
- 10 Dec 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov